Advances in oncolytic virotherapy

Stephen J Russell; John C Bell; Christine E Engeland; Grant McFadden

doi:10.1038/s43856-022-00098-4

Advances in oncolytic virotherapy

Commun Med (Lond). 2022 Apr 7:2:33. doi: 10.1038/s43856-022-00098-4. eCollection 2022.

Authors

Stephen J Russell^{1

2}, John C Bell³, Christine E Engeland^{4

5

6}, Grant McFadden^{7

8}

Affiliations

¹ Mayo Clinic, Rochester, MN USA.
² Vyriad, Rochester, MN USA.
³ Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON Canada.
⁴ Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
⁵ Department of Medical Oncology, University Hospital Heidelberg, Heidelberg, Germany.
⁶ Faculty of Health/School of Medicine, Institute of Virology and Microbiology, Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University, Witten, Germany.
⁷ Center for Immunotherapy, Vaccines, and Virotherapy (CIVV), Biodesign Institute, Arizona State University, Tempe, AZ USA.
⁸ OncoMyx Therapeutics, Phoenix, AZ USA.

Abstract

Recent years have seen rapid advances in the preclinical development and clinical evaluation of oncolytic (cancer-lysing) virus-based therapies, and these are emerging as treatment modality for some cancers. There are challenges to address, however, if we are to maximize the impact of these therapies in patients.